Sanixtra CZ s.r.o.
- Address
- Slunecni Namesti 2588, 158 00 Prague, Czechia
Sanixtra CZ s.r.o. - Lipid Metabolism Research Center
Sanixtra CZ s.r.o. is a specialized clinical research facility focused on investigating novel therapeutic interventions for severe lipid metabolism disorders. The center demonstrates particular expertise in conducting clinical trials for patients with complex dyslipidemia conditions that significantly impact cardiovascular health and quality of life.
- Severe hypertriglyceridemia (SHTG) treatment development
- Subcutaneous oligonucleotide therapy administration and monitoring
- Advanced lipid metabolism disorder management
The research center has established comprehensive protocols for evaluating olezarsen (ISIS 678354), an investigational antisense oligonucleotide therapy targeting elevated triglyceride levels. Their clinical trial programs assess both efficacy outcomes, including percent change in fasting triglycerides from baseline, and comprehensive safety and tolerability profiles. This dual focus on therapeutic effectiveness and patient safety demonstrates Sanixtra's commitment to advancing treatment options for individuals with severe hypertriglyceridemia, a condition associated with increased risk of acute pancreatitis and cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Incyte Corp.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sanixtra CZ s.r.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide | 2 | Unknown | 2024-12-17 | 2025-09-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.